In this weeks video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in combination with dexamethasone to treat multiple myeloma patients who are refractory to IMiDs, proteasome inhibitors, and daratumumab.
BOTTOM LINE: Selinexor will likely be approved by the FDA, demonstrating its safety and efficacy in combination with other myeloma therapies.
Advertisement